This new CLL score improved the sensitivity to 79.4% in the CD5-negative or CD23-negative CLL group compared to the Moreau score (41.2%) and CLL flow score (47.1%). This evidence concerns the gene FCER2 and B-cell chronic lymphocytic leukemia.